Company ProfilePremium

Palla Pharma Limited

Company Profile Analysis

Ticker: TPE.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Palla Pharma Limited - Company showcase

Year Founded & Workforce

2004

60 Employees

Palla Pharma Limited logo

Palla Pharma Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Palla Pharma Limited Overview

Palla Pharma, founded as TPI Enterprises by Jarrod Ritchie, was an Australian vertically integrated opiate manufacturer. It spanned the chain from contracted poppy cultivation and poppy-straw processing through to codeine phosphate active pharmaceutical ingredient (API) and tableted finished dosage forms (FDF). It was one of three licensed poppy processors in Australia and the only Australian-owned one. It described itself as one of six licensed opiate producers globally and one of three fully integrated suppliers from extraction to tableting. Its claimed differentiator was a proprietary, water-based alkaloid extraction process that it said was low-cost, needed a small workforce and was environmentally sustainable. From 2017 the company pursued a "move down the value chain" strategy. It acquired Vistin Pharma's Norwegian opiates and tableting business and later bought UK marketing authorisations so it could sell its own branded generics. Collapsing volumes, low opioid prices, COVID-driven cuts to elective surgery and rising losses led to administration in December 2021 and liquidation in 2022.


Company's own description (FY2020 annual report and 2020 ASX announcements). Palla Pharma described itself as a vertically integrated opiate manufacturer, from poppy straw through to tableting production. It said it had developed an innovative, efficient and environmentally sustainable opiate manufacturing process based on a novel water-based extraction technology. It called itself one of six licensed opiate producers globally and one of three fully integrated suppliers from opiate extraction to tableting. Data providers summarise the business as producing and distributing narcotic raw materials (NRM), APIs and FDF for pharmaceutical markets in Australia and Norway, plus poppy seed for culinary markets.

Independent characterisation. Palla was a sub-scale, capital-intensive commodity alkaloid processor trying to become a specialty generic-drug manufacturer. Its economic engine had three stages:

  1. Upstream (Australia, Coolaroo, Victoria). Poppy straw was sourced from contracted growers in Australia and the Northern Hemisphere (the company referred to "Australian and Northern Hemisphere supply sources" and had grower contracts in Portugal). The straw was processed into NRM, an alkaloid-rich concentrate mainly of morphine and codeine. By-product poppy seed was sold into culinary markets.

  2. Midstream (Norway, Kragerø). NRM was shipped from Melbourne to the Kragerø plant and converted into codeine phosphate API and pholcodine (a cough-suppressant opioid). The plant had come with the 2017 Vistin acquisition.

  3. Downstream (Norway, Kragerø, and the UK market). API was granulated and tableted into finished dosage forms. These were sold first as contract manufacturing for third parties, and from 2020–21 under Palla-owned UK marketing authorisations (MAs) such as a 30/500 co-codamol caplet.

Revenue model. Almost entirely product sales. The mix was NRM and poppy seed (B2B commodity), API (B2B supply contracts, typically multi-year with minimum tonnages), contract tableting (CMO), and own-MA FDF sales to UK wholesalers. There was no subscription or licensing revenue of note. One FY2020 disclosure referred to the termination of a "non-opiate based supply agreement", meaning lower-margin non-opiate contract work had also existed, probably legacy Vistin CMO tableting.

Value-chain position. Palla was a supplier to generic-drug formulators, contract manufacturers and, through its own MAs, UK pharmaceutical wholesalers. Customers included "one of Europe's leading pharmaceutical contract manufacturing organisations" (2018 contract), an unnamed European codeine phosphate customer (2019), a major UK-based multinational (2020 tablet extension), Sterling Pharma Solutions (UK, 2016 manufacturing and supply deal), an unnamed "global pharmaceutical company" (A$30 million deal, 2016), and Weifa (Norway, inherited from the Vistin CMO business).

End markets. Prescription and over-the-counter analgesics (codeine and co-codamol), cough and cold (pholcodine, codeine linctus), and culinary poppy seed. Demand was tied to surgical volumes and acute pain prescribing, which is why COVID-related elective-surgery cancellations, particularly in the UK, became the proximate trigger for failure.

Strategy

Stated strategic themes (2019–2021 company communications):

  1. "Move down the value chain." Capture margin at each stage from farm to pharmacy by converting low-cost NRM into API and then FDF.

  2. Downstream, margin-accretive own-MA FDF sales. The FY2020 report emphasised a focus on Palla MA FDF sales, possibly carried out through partners. Imminent supply of Palla generic FDF using its own MAs was presented as the future earnings growth engine.

  3. Capacity expansion. Kragerø codeine phosphate capacity expansion (2018–19). Plan to raise packaging capacity to more than 70 tonnes in calendar 2021, with targeted supply of 24 tonnes of codeine phosphate in tableted form.

  4. Low-cost NRM supply. Use Victorian NRM plus Northern Hemisphere sourcing to improve crop and alkaloid yields.

  5. Exit lower-margin non-opiate work (completed in 2020).

  6. Portugal API plant and poppy growing (2017 plan; not confirmed as executed).

Initiatives in the final 24 months (Dec 2019 – Dec 2021): acquisition of 11 UK MAs; abandoned acquisition of a UK tablet manufacturer; A$8 million UK tablet contract extension; MA site transfer to Norway (approved Feb 2021); March 2021 entitlement offer; CEO change (Giles Moss); strategic review (late 2021), which ended in administration.

Medium-term targets and guidance: FY2019 revenue guidance of A$60 million or more (missed: actual A$54.7 million). 2H FY2020 earnings were guided to be "significantly stronger" with a "material uplift" for the full year (not achieved: FY2020 operating EBITDA loss of about A$15.8 million). No subsequent quantitative guidance was verified. ESG commitments: beyond describing the extraction process as environmentally sustainable, none were publicly disclosed.

Products & Services

Product-level revenue: not publicly disclosed.

Product Portfolio

SegmentProduct / offeringDescriptionTarget customerLaunch / latestPricing / commercial modelNotes

Australia

Narcotic Raw Material (NRM) – morphine/codeine-rich concentrate

Alkaloid concentrate extracted from poppy straw using the proprietary water-based process

API manufacturers worldwide; internal transfer to Norway

Core product since the TPI era; Victorian plant

B2B tonnage contracts; prices not disclosed

NRM and poppy-seed revenue fell A$4.2 million in FY2020

Australia

Culinary poppy seed

By-product seed sold into international food markets

Food ingredient distributors

Ongoing to 2021

Commodity pricing

Reported together with NRM

Australia

Other alkaloids (thebaine, oripavine, noscapine)

Patent filings reference these alkaloids

API makers

——

Commercial volumes not publicly disclosed

Norway

Codeine phosphate API

Converted from NRM at Kragerø

European CMOs and generic formulators

Inherited from Vistin in 2017; capacity expanded 2018–19

Multi-year contracts: at least 6 t/yr (2018, over A$9 million over 3 years); 24 t/yr (2019, at least US$25 million)

Core growth product 2018–19

Norway

Pholcodine API

Opioid cough suppressant

Cough-syrup formulators

Inherited from Vistin

—

Vistin's second key product

Norway

Codeine phosphate granulate

Intermediate form for tableting

Formulators

2019 contract allowed supply as API, granulate or tablets

Contracted

—

Norway

Contract tablet manufacturing (CMO)

Tableting for third parties

UK multinational (270 million tablets, A$8 million, 2020–21); Weifa (legacy)

Ongoing

Per-tablet contract

A non-opiate contract was terminated in 2020, reducing revenue

Norway / UK

Palla-owned MA FDF: co-codamol 30/500 caplets

Own-brand codeine/paracetamol caplet for the UK

UK wholesalers and pharmacy

Validation 2020; site transfer approval Feb 2021

Branded generic; the company said MA sales roughly doubled revenue per unit (over A$1 million versus A$0.5 million sold as API on a comparable basis)

Flagship of the downstream strategy

Norway / UK

Other acquired UK MAs (11 in total: 4 plus 7)

Codeine-based products bought from distressed UK customer

UK market

Acquired 1H 2020

Branded generic

Individual product names not publicly disclosed

Technology

Water-based extraction process

Proprietary poppy-straw extraction

Internal

Developed in the TPI era

Not licensed externally

Claimed to need 50–60 staff for 80 tonnes a year versus 100–150 at peers

“—” = not publicly disclosed.

Financial Narrative

Data availability. Palla's last full-year audited accounts were for FY2020 (year ended 31 December 2020, released 19 March 2021). The last interim accounts covered 1H 2021. No FY2021 accounts were lodged: the administrators relied on exemptions from financial reporting under Part 2M.3, and ASX waivers were refused. Where possible, figures are cross-checked between the FY2020 annual report (via AspectHuntley), Market Index and Investing.com.

Income statement: notes and sources

Sources: FY2020 annual report (sales of A$21.9 million versus A$54.7 million; statutory loss of A$34,756,056 versus A$7,639,443; operating EBITDA loss up by A$15.5 million from A$0.3 million); Market Index (trading revenue, NPAT and abnormals). Gross profit is the analyst's estimate from the 1H 2019 gross margin of 34.6% on A$27.3 million plus aggregator 2H figures.

Half-year income statement: notes and sources

Sources: 1H2019 revenue and gross margin from Retail Pharmacy Magazine (company results); 1H2019 net income derived (FY2019 minus 2H2019); other periods from Investing.com. Note: Investing.com labels some periods as "12 months", but the values reconcile to half-years (for example, 1H2020 plus 2H2020 = A$22.1 million versus FY2020 sales of A$21.9 million), so they are treated as half-years here. 1H2019 underlying net loss was reported as A$2.3 million.

Balance sheet

Source: Investing.com. Cash and equivalents, total debt (short- and long-term split), net debt, goodwill and intangibles, and working capital: not publicly disclosed in retrieved sources. Net tangible assets per share were 34 cents at 30 June 2020, down 5.6% (Biotech Daily).

Equity fell by about 72% in 18 months (A$71.4 million to A$20.1 million) while liabilities rose by 64%. By June 2021 the company had lost most of the equity raised in October 2019 and March 2021. The write-down of acquired MAs and Norwegian assets is a likely driver of the large 1H 2021 loss, but the composition of that loss is not disclosed in the retrieved data.

Cash flow

Source: Investing.com (period labelling ambiguity noted in 6.2). Capex, free cash flow, dividends paid and buybacks: not separately disclosed. No dividends or buybacks were ever made.

Operating cash burn rose from about A$9 million a half in 2H2019 to over A$13 million a half in 2021. Financing inflows of A$11–14 million every half-year show the business depended entirely on repeated equity raisings and borrowings.

Ratios (derived by the analyst)

ROE, ROA and asset turnover for FY2020 use average equity (A$53.8 million) and average assets (A$78.5 million). ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage and cash conversion cycle: not publicly disclosed (debt and working-capital components unavailable). Interest coverage was negative in any case, since EBITDA was negative.

Commentary on trends, inflections and drivers

Peak and inflection (2019). FY2019 was the high-water mark: sales of A$54.7 million and a near-breakeven operating EBITDA (loss of A$0.3 million). This was driven by codeine phosphate API contracts, including the 24 t/yr European agreement, and tableting for a large UK customer. The company had guided to A$60 million or more and reported a "modest, maiden" half-year operating EBITDA profit in 1H 2019.

Collapse (2020). Revenue fell 60% as Palla deliberately exited lower-margin non-opiate contract work and as its largest UK customer suspended manufacturing. Palla supported that customer with working capital and bought its MAs, but the regulatory site transfer slipped to February 2021, leaving the Norwegian plant underused. COVID-19 cut elective-surgery volumes. Gross margin turned negative in 2H 2020. A A$1.0 million trade-receivables impairment was booked on API shipped in 2019 to the major customer. Abnormal items of A$15.1 million produced a statutory loss of A$34.8 million.

Terminal decline (2021). 1H 2021 revenue fell another 43% to A$7.1 million and the half-year loss was A$33.1 million. Labour costs in SG&A rose 19% to A$5.8 million even as revenue fell. The own-MA strategy did not deliver volume quickly enough, and the Omicron wave in late 2021 hit UK elective surgery again.

Overall. Palla never produced a full-year statutory profit in the period for which data is available. Revenue CAGR FY2019–FY2020 was -59.9%.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionRoleFate

Palla Pharma Limited

Australia

Listed parent; Coolaroo NRM and poppy-seed operations; head office

Liquidated; deregistered 7 Feb 2026

Palla Pharmaceuticals Pty Ltd

Australia

Australian subsidiary (named in auction materials as "In Liquidation")

Liquidated

Palla Pharma Norway Holdings AS

Norway

Holding company for Norwegian operations

Sold 28 Mar 2022 to Norwegian consortium

Palla Pharma Norway AS (formerly TPI Norway AS)

Norway

Kragerø API and FDF manufacturing

Sold 28 Mar 2022; continues trading privately

Palla Pharma (UK) Limited

United Kingdom

UK commercial entity, likely holding UK MAs and wholesaling

Sold 19 Mar 2022 to Norwegian consortium

Revenue by Segment and Segment Margins & Growth (%)

Segment1H20201H2021

Norway segment revenue (AUD Mn)

9.846.2

Australia segment revenue (AUD Mn)

2.540.863

Total revenue (AUD Mn)

12.337.06

Segment metric

1H2021

—

Norway YoY growth (%)

-37—

Australia YoY growth (%)

-66—

Norway share of total revenue (%)

87.8—

Australia share of total revenue (%)

12.2—

Income Statement and Margin Analysis (%)

MetricFY2019FY2020

Sales revenue (AUD Mn)

54.6921.91

Revenue growth YoY (%)

—-59.9

Gross profit (AUD Mn, derived from half-years)

17.4-1.06

Gross margin (%, derived)

31.8-4.8

Operating EBITDA (AUD Mn)

-0.3-15.8

Statutory NPAT (AUD Mn)

-7.64-34.76

Abnormal / significant items (AUD Mn)

-2.04-15.1

NPAT before abnormals (AUD Mn)

-5.6-19.66

Net margin on sales (%, derived)

-14.0-158.6

Dividends per share (AUD)

00

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (1H2019–1H2021)

Metric1H20192H20191H20202H20201H2021

Total revenue (AUD Mn)

27.327.4912.339.787.06

Gross profit (AUD Mn)

9.457.951.79-2.85-3.5

Gross margin (%)

34.628.914.5-29.1-49.6

Operating income (AUD Mn)

—-2.08-8.02-24.7-32.17

Net income (AUD Mn)

-4.08-3.56-9.01-25.74-33.11

Balance Sheet and Financial Ratios (x)

MetricDec2019Jun2020Dec2020Jun2021

Total assets (AUD Mn)

89.5786.1767.4249.89

Total liabilities (AUD Mn)

18.1624.4331.329.82

Total equity (AUD Mn)

71.4161.7436.1220.07

Liabilities to equity (x, derived)

0.250.400.871.49

Cash Flow

Metric2H20191H20202H20201H2021

Operating cash flow (AUD Mn)

-9.47-5.44-14.78-13.35

Investing cash flow (AUD Mn)

-2.48-2.150.77-0.38

Financing cash flow (AUD Mn)

11.697.3712.5313.93

Net change in cash (AUD Mn)

0.11-0.37-1.410.29

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2020

ROE (%)

-64.6

ROA (%)

-44.3

Asset turnover (x)

0.28

Revenue by Region

Region1H20201H2021

Norway (AUD Mn)

9.846.2

Australia (AUD Mn)

2.540.863

Region

1H2021 YoY growth (%)

—

Norway

-37—

Australia

-66—

Share Price History

DatePrice (AUD)Context

28 Oct 2015

3.45

Director on-market purchase

31 May 2016

3.10

Director purchase

Jul 2017

2.42

After Vistin deal (+10%)

1 Sep 2017

2.391

Director purchase

2 Mar 2018

1.36

Director purchase

16 Oct 2019

0.90

Last trade before raise

Oct 2019

0.70

Placement and entitlement price

26 May 2020

0.80

After +12.7% day

31 Aug 2020

0.80

After 1H20 result (-11%)

Mar 2021

0.50

Entitlement price

12 Apr 2021

0.476

Director purchase

9 Jun 2022

0

Declared worthless

Analyst Conclusions

Management guidance / consensus: not applicable. The entity has been liquidated and deregistered.

Bull case (as it stood in 2020–21, with hindsight)

  1. Own-MA FDF economics: revenue per unit roughly double API, through owned UK MAs.

  2. Contracted API base: at least US$25 million over 3 years plus over A$9 million over 3 years.

  3. Strategic asset value: Kragerø proved saleable as a going concern and still operates.

Bear case (borne out)

  1. Losses accelerated from -A$7.6 million to -A$34.8 million to -A$33.1 million per half while revenue fell by about 87% from the 2H2019 run-rate.

  2. Equity eroded from A$71.4 million to A$20.1 million in 18 months, with operating cash burn above A$13 million per half.

  3. Exogenous demand shocks (pandemic, low opioid prices) against a high fixed-cost, two-continent structure.

Monitorables for the next 12 months: for Palla Pharma Limited, none. For the successor Palla Pharma Norway AS (private): Norwegian annual accounts (Brønnøysund register), European codeine supply-security developments, and UK MA ownership.

Analyst verdict. Palla Pharma's failure illustrates the risks of a sub-scale commodity producer trying to buy its way into specialty margins without the balance sheet to survive the transition. The strategic logic was sound on paper: own low-cost NRM, convert it to API in Europe, and sell branded tablets under owned MAs to capture the whole margin stack. The 2017 Vistin acquisition at about 5.6x EBITDA gave TPI a real downstream platform, and 2019 showed what it could earn at volume: A$54.7 million of sales and a near-breakeven operating EBITDA.

The model was fragile, though. NRM was produced in Melbourne and converted in Kragerø, which doubled the fixed-cost base and tied up working capital in shipments of controlled substances. Revenue was concentrated, so when the largest UK customer faltered Palla absorbed its problems by buying its MAs, and then waited about a year for regulators to approve the manufacturing transfer. COVID-19 then cut the elective-surgery demand that drives codeine and co-codamol use, and opioid prices stayed low.

The numbers show the result. Sales fell 60% in FY2020, gross margin turned sharply negative, equity fell by 72% in 18 months, and the company depended on capital raises that retail investors increasingly declined. A founder-CEO exit in December 2020 and a new CEO in September 2021 came too late.

The administration outcome is instructive. No buyer would take on the Australian plant, and Coolaroo was closed and auctioned. The Norwegian business was bought by local investors and continues to trade, which suggests the downstream assets had standalone value while the Australian upstream operation was the stranded cost. For investors the lesson is clear: in licensed, oligopolistic industries, scale and a strong balance sheet matter more than process innovation. Shareholders lost everything; creditors were expected to recover between 6 and 84 cents in the dollar. The entity has now ceased to exist.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / educationCompensation

Giles Moss

CEO

1 Sep 2021 – administration

VP and GM Europe, GW Pharmaceuticals (to Jul 2021); also CEO of Sapient Therapeutics; University of Manchester (undergraduate), Henley Management College (MBA); more than 30 years of pharma commercial leadership

—

Paul Sherman

CFO

19 Oct 2021 – administration

——

Brendan Middleton

CFO; interim CEO (Dec 2020 – Aug 2021)

12 Apr 2017 – 19 Oct 2021

——

Jarrod Ritchie

Founder, MD and CEO

5 Feb 2004 – 22 Dec 2020

Founder; led the company for about 17 years

Not publicly disclosed in retrieved sources

Craig Sweenie

Site Director, Norway (former)

—

Named in LinkedIn post by former employee

—

Marit Risberg

Quality and Regulatory Director, Norway (former)

—

As above

—

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedCeasedNotes

Simon Moore

—

1 Jun 2016

23 May 2022

Founder of Colinton Capital; former Carlyle country head; also a shareholder

Stuart Black

Non-executive director

7 Jun 2016

21 Apr 2022

IBISWorld lists him as CEO, apparently in error.

Sue MacLeman

Non-executive director

27 Nov 2018

21 Apr 2022

—

Iain Ross

Non-executive director

23 Dec 2020

21 Apr 2022

Bought 75,000 shares at A$0.476 (about A$35,700) on 12 Apr 2021

Todd Barlow

Non-executive director

18 Jun 2015

4 Feb 2021

CEO of Washington H. Soul Pattinson (major shareholder)

Peter Robinson

Chairman

1 Feb 2013

1 May 2018

Bought 25,000 shares at A$1.36 in Mar 2018

Jarrod Ritchie

Managing Director

5 Feb 2004

22 Dec 2020

Founder

Major Shareholders

HolderStake

Other top-10 holders

Not publicly disclosed in retrieved sources

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning relative to Palla

Tasmanian Alkaloids (Tasmania; owned by SK Capital alongside Noramco from 2016)

Australian poppy processing, NRM, thebaine/oripavine

Much larger Australian processor with established grower base

Sun Pharmaceutical Industries (Tasmanian opiates business acquired from GSK, 2015)

Australian poppy processing, NRM and API

Integrated within a global generics major

Noramco (US)

Opiate API

Large API supplier to the US market

SpecGx / Mallinckrodt (US)

Opiate API and generics

Dominant US opioid API and generic supplier

Macfarlan Smith (UK; formerly Johnson Matthey)

Opiate API, codeine, UK market

Direct UK and European API competitor

Alcaliber (Spain)

Poppy cultivation, NRM, API

Integrated European competitor

Francopia (France)

Opiate API

European API competitor

Siegfried (Switzerland)

Controlled-substance APIs

Large CDMO with narcotics capability

Government opium and alkaloid works, India (Ghazipur, Neemuch)

NRM from opium gum

State-run supply under the INCB traditional-supplier framework

UK generic FDF makers (various)

Co-codamol and codeine tablets

Competitors for the own-MA strategy

Recent Developments

The standard 18-month window (April 2025 – October 2026) has no corporate activity other than deregistration.

Company Snapshot

$5.3M

Revenue

60

Employees

2004

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Full vertical integration from poppy straw to tablets. The company described itself as one of three fully integrated suppliers worldwide (2020 ASX announcements).
  • Low-labour extraction technology: 50–60 staff for 80 t/yr versus 100–150 at peers (Shaw and Partners, Oct 2019).
  • Scarce licence position: one of three Australian licensed poppy processors and the only Australian-owned one.
  • Kragerø API and FDF site with decades of pharmaceutical history (Vistin had more than 65 years of experience in 2017). It proved valuable enough to be sold as a going concern in 2022.
  • Contracted API offtake: at least US$25 million over 3 years (2019) and over A$9 million over 3 years (2018).
  • Own UK MAs (11 acquired in 2020). The company said these roughly doubled revenue per unit compared with API sales (over A$1 million versus A$0.5 million).

Weaknesses

  • Persistent losses: FY2019 NPAT -A$7.6 million, FY2020 -A$34.8 million, 1H2021 -A$33.1 million.
  • Revenue collapse: -60% in FY2020 and -43% in 1H2021.
  • Negative gross margins from 2H2020 (-29% in 2H2020, -50% in 1H2021, derived).
  • Cash burn: operating cash outflow of A$13–15 million per half in 2020–21, funded by repeated raises.
  • Customer concentration: the suspension of the largest UK customer derailed 2020, and a A$1.0 million receivable was impaired.
  • Execution slippage: missed FY2019 guidance (A$54.7 million versus A$60 million or more), missed the 2H2020 uplift, and the MA transfer slipped to Feb 2021.

Opportunities

  • Own-MA FDF sales capturing the full margin from farm to pharmacy.
  • Norwegian packaging expansion to more than 70 tonnes a year (2021 plan).
  • Northern Hemisphere sourcing (Portugal) to improve yields.
  • Recovery of elective surgery after COVID.
  • Consolidation: buying a distressed UK tableting site with more than 120 t capacity (explored 2019–20).
  • Supply-security demand in Europe. The successor Norwegian company now promotes its role in securing codeine supply for Europe (Business Norway).

Threats

  • Depressed global opioid prices (administrators, Feb 2022).
  • Pandemic disruption to elective surgery (company and administrators, Dec 2021 and Feb 2022).
  • Larger integrated competitors (Sun Pharma, Tasmanian Alkaloids/Noramco, Macfarlan Smith).
  • Regulatory and licensing risk (MA transfers, narcotics licences).
  • Funding risk: a 53.8% retail take-up in March 2021 signalled investor fatigue.
  • Societal and regulatory pressure on opioid prescribing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
26 May 2020UK acquisition talks ended; 7 MAs retained; 2H guidance "significantly stronger"Strategy pivot to own MAs
28 May 2020AGM with trading update—
17 Jul 2020A$8 million UK tablet contract extension; co-codamol caplet validationFDF volume
31 Aug 20201H 2020 results: revenue A$12.3 million (-55%), loss A$9.0 million; shares fall 11% to A$0.80Deterioration visible
6 Nov 2020CCZ Equities research note expects a profitable 2021 from the MAsLast bullish broker view found
22 Dec 2020Founder CEO Jarrod Ritchie resigns with immediate effect; CFO Middleton interim CEOLeadership shock
23 Dec 2020Iain Ross joins board—
4 Feb 2021Todd Barlow (Soul Patts) leaves boardWeakening anchor-shareholder engagement
Feb 2021MA manufacturing site transfer to Norway approvedDelayed from late 2020
19 Mar 2021FY2020 annual report: statutory loss A$34.8 million—
Mar 20212-for-9 entitlement offer at A$0.50; 53.8% retail take-upWeak retail support
12 Apr 2021Director Iain Ross buys 75,000 shares at A$0.476Insider buying
1 Sep 2021Giles Moss appointed CEONew leadership
Aug–Sep 20211H 2021 results: revenue A$7.1 million (-43%), loss A$33.1 millionEquity nearly exhausted
19 Oct 2021Paul Sherman appointed CFO—
15 Dec 2021Trading suspended pending strategic review—
17 Dec 2021Voluntary administration (KordaMentha); about 60 employees; Omicron impact on elective surgery citedInsolvency
29 Dec 2021Expressions of interest advertised in the Australian Financial ReviewSale process
12–19 Jan 2022Federal Court extends convening period to 27 Apr 2022—
27 Jan 2022Financial reporting and AGM deferral—
31 Jan 2022Indicative offers; two parties advance—
14–16 Feb 2022Both bidders withdraw; Coolaroo wind-down starts; ASX waivers refusedEnd of going-concern hope
2 Mar 2022Administrators recommend liquidation; estimated 6–84 c/$ to unsecured creditors—
9 Mar 2022Liquidation resolved—
19 & 28 Mar 2022UK and Norwegian subsidiaries sold to Norwegian consortiumOperating assets survive under new owners
12 Apr 2022Coolaroo plant auction opensAustralian assets dispersed
21 Apr & 23 May 2022Remaining directors cease—
9 Jun 2022Shares declared worthlessTotal shareholder loss
15 Jul 2022Notice of third and final dividend (to be declared 15 Sep 2022; proofs due 5 Aug 2022)Creditor distributions
26 Jul / 2 Aug 2022Delisting notice; removal from Official ListEnd of listing
9 Apr 2024Liquidator's activity report lodged with ASIC—
6 Nov 2025Winding-up completed—
7 Feb 2026DeregistrationEntity ceases to exist

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Total revenue fell from AUD 12.3 Mn in 1H 2020 to AUD 7.1 Mn in 1H 2021.
Palla Pharma Limited — Revenue by Segment
Series (AUD Mn)1H 20201H 2021
Total revenue12.37.1
Norway segment revenue9.86.2
Australia segment revenue2.50.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. ASX Online: Suspension of Approval notice, 17 Dec 2021. (asxonline.com)
  2. deListed Australia: Palla Pharma Limited (company register, announcements timeline, directors, ISIN, deregistration). (delisted.com.au)
  3. ASIC Published Notices: Notice of intention to declare dividend, 15 Jul 2022. (publishednotices.asic.gov.au)
  4. KordaMentha: Palla Pharma Limited enters voluntary administration (Dec 2021).: KordaMentha.com
  5. KordaMentha: Liquidators' statutory report, 9 Jun 2022. (kordamentha.com)
  6. Liquidators' declaration on shares, 9 Jun 2022. (investogain.com.au)
  7. Listcorp: Voluntary delisting update (Jul 2022). (listcorp.com)
  8. Hymans: Liquidators auction, Palla Pharma Ltd. (hymans.com.au)
  9. Palla Pharma Annual Report FY2020 (via AspectHuntley). (aspecthuntley.com.au)
  10. ASX announcement, 23 Jul 2019: New codeine phosphate supply agreement. (asx.com.au)
  11. ASX announcement, 17 Jul 2020: FDF contract extension. (asx.com.au)
  12. ASX announcement, 3 Aug 2018: TPI 3-year codeine phosphate contract. (asx.com.au)
  13. Investing.com: Palla Pharma financial summary. (m.uk.investing.com)
  14. Market Index: PAL financials. (marketindex.com.au)
  15. Motley Fool Australia, 26 May 2020. (fool.com.au)
  16. Shaw and Partners, 17 Oct 2019: capital raising. (shawandpartners.com.au)
  17. Arnold Bloch Leibler: A$31.1 million capital raising. (abl.com.au)
  18. Biotech Daily, 31 Aug 2020. (biotechdaily.com.au)
  19. Retail Pharmacy Magazine: 1H19 results. (retailpharmacymagazine.com.au)
  20. Strawman member reports (CEO changes, entitlement offer). · strawman.com
  21. Zonebourse: Giles Moss profile. (zonebourse.com)
  22. FNN: TPI buys European opiate business (Jul 2017). (finnewsnetwork.com.au)
  23. DCAT Value Chain Insights: Vistin sells CMO business. (dcatvci.org)
  24. Vistin Pharma releases (GlobeNewswire / BioSpace), 11–13 Jul 2017. (globenewswire.com)
  25. Outsourcing-Pharma: TPI buys Vistin assets, Portugal plan. (outsourcing-pharma.com)
  26. SmallCaps: TPI codeine phosphate supply deal. (smallcaps.com.au)
  27. Business Norway: Palla Pharma Norway AS. (businessnorway.com)
  28. FINN.no job listing: Palla Pharma Norway AS (Kragerø). (finn.no)
  29. Patsnap Discovery: Palla Pharma patents. (discovery.patsnap.com)
  30. IBISWorld: Palla Pharma Limited enterprise profile. (img3.ibisworld.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.